Skip Ribbon Commands
Skip to main content
CIBMTR

Study Lists

Sharing knowledge. Sharing Hope.
Skip Navigation LinksHome   /   Studies   /   Clinical Outcomes Research   /   Study Lists   /   Observational Studies
  • Print
  • Share

 


Plasma Cell Disorders and Adult Solid Tumors Working Committee Studies

The Plasma Cell Disorders and Adult Solid Tumors Working Committee provides scientific oversight for studies related to hematopoietic cell transplantation for multiple myeloma, other plasma cell disorders and adult solid tumors.

Learn more about the studies conducted through the Plasma Cell Disorders and Adult Solid Tumors Working Committee using the links below.

Recently Completed Studies

NumberTitleStatus
MM14-03 Trends in survival outcomes among patients relapsing early after autologous stem cell transplantation for multiple myeloma Published
MM14-02 Autologous hematopoietic cell transplantation in patients with renal insufficiency Published
MM13-02 Outcome of tandem autologous hematopoietic cell transplantation in patients with abnormality in chromosome 1 and high-risk multiple myeloma Published
MM13-01 Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation Published
MM11-04 High-dose intravenous busulfan and melphalan followed by bortezomib (BuMelVel) vs high-dose melphalan (Mel) as conditioning regimen for autologous peripheral blood stem cell transplantation for patients with multiple myeloma Published
MM11-03b Validation of 2012 hematologic response criteria for AL amyloidosis in the autotransplant CIBMTR cohort with availability of FLC data Published
MM11-03a Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: A Center for International Blood and Marrow Transplant Research Study Published
MM11-02 Waldenstrom’s macroglobulinemia: retrospective analysis with hematopoietic cell transplantation Published
MM11-01 Older patients with myeloma derive similar benefit from autologous transplantation. Published
ST10-01 The value of high-dose chemotherapy and autologous hematopoietic cell transplantation as adjuvant treatment in patients with high-risk inflammatory breast cancer after neoadjuvant chemotherapy Published
MM10-01 New cancers after autotransplants for multiple myeloma Published
MM08-02 HLA-C*07:02 is associated with increased risk of multiple myeloma Published
MM06-04 Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma Published
MM17-G1 Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances. Published
MM15-03 Race and outcomes of autologous stem cell transplantation for multiple myeloma in Hispanic patients Published
MM15-02 Post-relapse survival rates after tandem autologous hematopoietic cell transplantation in multiple myeloma Published
MM15-01 The impact of novel agent induction regimen choice on autologous hematopoietic cell transplantation for newly diagnosed multiple myeloma Published

Last Updated: 12/7/2017 11:36 AM
CIBMTR